JP2016525516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525516A5 JP2016525516A5 JP2016526515A JP2016526515A JP2016525516A5 JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5 JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mutation
- cytokine
- mutated
- leptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000695 Cytokines Proteins 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 102000016267 Leptin Human genes 0.000 claims 4
- 108010092277 Leptin Proteins 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 4
- 229940039781 leptin Drugs 0.000 claims 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 3
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 2
- 102100035304 Lymphotactin Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102200154281 rs267606652 Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034.3 | 2013-07-18 | ||
| EP13306034 | 2013-07-18 | ||
| PCT/EP2014/064227 WO2015007536A2 (en) | 2013-07-18 | 2014-07-03 | Fusokines involving cytokines with strongly reduced receptor binding affinities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Division JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525516A JP2016525516A (ja) | 2016-08-25 |
| JP2016525516A5 true JP2016525516A5 (https=) | 2017-08-10 |
| JP6580037B2 JP6580037B2 (ja) | 2019-09-25 |
Family
ID=48906191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526515A Active JP6580037B2 (ja) | 2013-07-18 | 2014-07-03 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10640542B2 (https=) |
| EP (2) | EP3299466B1 (https=) |
| JP (2) | JP6580037B2 (https=) |
| KR (1) | KR102322510B1 (https=) |
| CN (2) | CN110835376B (https=) |
| AU (2) | AU2014292371B2 (https=) |
| BR (1) | BR112016001036B1 (https=) |
| CA (1) | CA2917937C (https=) |
| DK (1) | DK3299466T3 (https=) |
| ES (2) | ES2657060T3 (https=) |
| IL (1) | IL243451B (https=) |
| MX (1) | MX375441B (https=) |
| SG (2) | SG10201808738WA (https=) |
| WO (1) | WO2015007536A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3580230B1 (en) * | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US12091463B2 (en) | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| WO2020257412A1 (en) | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| EP4178609A4 (en) * | 2020-07-07 | 2024-07-24 | Orionis Biosciences, Inc. | IMMUNOSTIMULATORY ADJUVANTS |
| CA3197371A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| EP4329786A4 (en) * | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| US20240166706A1 (en) * | 2022-11-21 | 2024-05-23 | Wisconsin Alumni Research Foundation | Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2055445T3 (es) * | 1989-08-22 | 1994-08-16 | Immunex Corp | Proteinas de fusion que comprenden gm-csf e il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| JP4793971B2 (ja) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| WO2008014612A1 (en) * | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| CA2779512C (en) * | 2009-11-02 | 2017-01-17 | Leonard H. Rome | Vault complexes for cytokine delivery |
| CN108295087B (zh) * | 2009-12-23 | 2021-01-15 | 格兰达利斯有限公司 | 弗林蛋白酶敲减和gm-csf增强的(fang)癌症疫苗 |
| AU2011243965A1 (en) * | 2010-04-22 | 2012-12-06 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | High affinity leptins and leptin antagonists |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CN104245734B (zh) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| ES2800426T3 (es) | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| CA2965414C (en) * | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
-
2014
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en not_active Ceased
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 MX MX2016000611A patent/MX375441B/es active IP Right Grant
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active Active
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US12410222B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525516A5 (https=) | ||
| Reber et al. | Targeting mast cells in inflammatory diseases | |
| Lichtenberg | Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009 | |
| Weitzenfeld et al. | The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer | |
| JP2016529232A5 (https=) | ||
| Koelink et al. | Targeting chemokine receptors in chronic inflammatory diseases: an extensive review | |
| Fedderke et al. | Does massive funding support of researchers work?: Evaluating the impact of the South African research chair funding initiative | |
| JP2016527221A5 (https=) | ||
| EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| JP2016515522A5 (https=) | ||
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| WO2018102787A9 (en) | Methods for determining car-t cells dosing | |
| JP2017206548A5 (https=) | ||
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| BR112016019837A2 (pt) | plasmídeos imunoestimuladores | |
| WO2015160928A3 (en) | Isolated t cell receptors and methods of use therefor | |
| EP3243830A4 (en) | Protein associated with disease resistance and encoding gene thereof, and use thereof in regulation of plant disease resistance | |
| WO2016081885A3 (en) | Panel-based genetic diagnostic testing for inherited eye diseases | |
| CN110198953A (zh) | 针对ny-eso的高亲和力tcr | |
| EP3875470A4 (en) | CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF | |
| EP3843761A4 (en) | Chimeric oncolytic herpesvirus that stimulate an antitumor immune response | |
| HRP20251546T1 (hr) | Elastični i klizni valvularni spoj, pogodan za rad u prethodno napunjenim špricama i navedene šprice | |
| Starzyńska et al. | III ogólnopolska konferencja naukowa „Zarządzanie współczesnymi przedsiębiorstwami. Współczesne problemy gospodarcze w oczach młodego pokolenia”: Third National Scientific Conference „Managing today's enterprises. Contemporary economic problems in the eyes of the young generation” | |
| JP2016113832A5 (https=) | ||
| 王桂云 | Lesson14 would you like some soup? |